Trial Profile
An open-label, prospective study to assess the efficacy, safety and tolerability of 36 weeks lamotrigine in the prevention of mood episodes in subjects with bipolar disorder, who are in remission following a manic/hypomanic index episode or a depressive index episode
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Lamotrigine (Primary)
- Indications Bipolar disorders
- Focus Registrational; Therapeutic Use
- Sponsors GSK
- 08 Nov 2006 New trial record.